Pangaea Oncology S.A. (PANG) - Total Liabilities
Based on the latest financial reports, Pangaea Oncology S.A. (PANG) has total liabilities worth €10.05 Million EUR (≈ $11.75 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Pangaea Oncology S.A.'s assets to evaluate the company's liquid asset resilience ratio.
Pangaea Oncology S.A. - Total Liabilities Trend (2013–2025)
This chart illustrates how Pangaea Oncology S.A.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Pangaea Oncology S.A. assets under control.
Pangaea Oncology S.A. Competitors by Total Liabilities
The table below lists competitors of Pangaea Oncology S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sunview Group Bhd
KLSE:0262
|
Malaysia | RM351.45 Million |
|
Unifosa
TWO:8277
|
Taiwan | NT$30.92 Million |
|
Zomedica Pharmaceuticals Corp
NYSE MKT:ZOM
|
USA | $10.55 Million |
|
Inter Industries
TA:ININ
|
Israel | ILA348.93 Million |
|
Man Zai Industrial Co Ltd
TWO:4543
|
Taiwan | NT$748.77 Million |
|
Remed Co.Ltd
KQ:302550
|
Korea | ₩16.62 Billion |
|
Covalon Technologies Ltd.
V:COV
|
Canada | CA$6.41 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down Pangaea Oncology S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Pangaea Oncology S.A. to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pangaea Oncology S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pangaea Oncology S.A. (2013–2025)
The table below shows the annual total liabilities of Pangaea Oncology S.A. from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €10.05 Million ≈ $11.75 Million |
+5.02% |
| 2024-12-31 | €9.57 Million ≈ $11.19 Million |
-4.55% |
| 2023-12-31 | €10.03 Million ≈ $11.72 Million |
+89.10% |
| 2022-12-31 | €5.30 Million ≈ $6.20 Million |
-21.63% |
| 2021-12-31 | €6.76 Million ≈ $7.91 Million |
-21.40% |
| 2020-12-31 | €8.61 Million ≈ $10.06 Million |
+0.50% |
| 2019-12-31 | €8.56 Million ≈ $10.01 Million |
-27.04% |
| 2018-12-31 | €11.74 Million ≈ $13.72 Million |
-15.61% |
| 2017-12-31 | €13.91 Million ≈ $16.26 Million |
+16.96% |
| 2016-12-31 | €11.89 Million ≈ $13.90 Million |
+19.45% |
| 2015-12-31 | €9.95 Million ≈ $11.64 Million |
+45.67% |
| 2014-12-31 | €6.83 Million ≈ $7.99 Million |
+45.04% |
| 2013-12-31 | €4.71 Million ≈ $5.51 Million |
-- |
About Pangaea Oncology S.A.
Pangaea Oncology, S.A., a precision oncology company, provides a range of services to cancer patients in Spain and the rest of European Union countries. The company offers molecular diagnostics, including mutation analysis in tissue and liquid biopsy; gene amplification and translocation testing; immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH); gene expression profiling a… Read more